HoneyNaps develops SOMNUM, an AI sleep diagnosis algorithm that analyzes biosignal data during sleep and provides disease diagnoses in under five minutes. The company obtained FDA approval for SOMNUM in 2023 and has partnered with major U.S. university hospitals via its Boston branch. HoneyNaps spent nine years developing X.AI (eXplainable AI), has registered 16 original patents and published SCIE-level research to support its clinical positioning. Management says domestic sales growth and export potential to the American medical market were key drivers of investor interest. The company plans to advance its AI beyond sleep diagnosis into applications such as cardiovascular disease, dementia, and Parkinson’s disease. Financially, HoneyNaps has raised about $16.2M to date, including seed funding of roughly $0.7M in 2019 and a $3.9M Series A in 2021.

Total raised

$12M

Funding rounds

1

Latest round

Series B

Latest activity

May 2024